The COVID-19 and Cancer Consortium: NCI Administrative Supplement to P30 Cancer Center Support Grant (CCSG)

COVID-19 和癌症联盟：NCI 对 P30 癌症中心支持补助金 (CCSG) 的行政补充

• 批准号: 10332040
• 负责人: JENNIFER A PIETENPOL
• 金额: $ 60万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-05-01 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10332040
• 关键词: 2019-nCoV; Acute; Administrative Supplement; Advocate; Affect; Age-Years; Antineoplastic Agents; Automobile Driving; Blood Transfusion; COVID-19; COVID-19 morbidity; COVID-19 patient; Canada; Cancer Center Support Grant; Cancer Patient; Case Study; Categories; Cessation of life; Chronic Obstructive Airway Disease; Colorectal Cancer; Community Networks; Community Practice; Comprehensive Cancer Center; Consultations; Data Analyses; Data Collection; Databases; Disease; Goals; Health Professional; Healthcare Systems; Image; Immunocompromised Host; Incidence; Inflammatory Bowel Diseases; Infusion procedures; Institution; Knowledge; Malignant Neoplasms; Malignant neoplasm of lung; Marrow; Mexico; NCI-Designated Cancer Center; Nature; Participant; Patients; Pharmaceutical Preparations; Provider; Publishing; Research; Risk; Site; Social Work; Steroids; Supportive care; Toxic effect; Translational Research; Venous blood sampling; Virus; Visit; Work; arm; cancer cell; cancer therapy; comorbidity; data cleaning; data dissemination; data registry; data resource; emerging pathogen; high risk; mortality; novel virus; pandemic disease; prospective; quality assurance; ranpirnase; social media; viral transmission

Project Summary COVID-19, the disease caused by the SARS-coV-2 virus, has now affected nearly 100 million people globally, with nearly 2 million deaths. Patients with cancer have a unique risk profile in this pandemic. Many patients, especially those actively on treatment, have high levels of contact with the health care system. This can include provider visits, phlebotomy, imaging, social work and financial consultations, and infusion room visits for anti-cancer therapy and supportive care such as blood transfusions. Despite heroic efforts to reduce viral transmission in these shared spaces, patients are at an increased risk for COVID-19 exposure. Additionally, most cancer patients are immunocompromised through the marrow toxic effects of anti-cancer drugs, supportive medications such as steroids, and/or the cancer itself; and over 60 years of age, putting them in the highest-risk category for COVID-19-related morbidity and mortality. Finally, incidences of important comorbidities can be considerably elevated in several cancers, such as chronic obstructive pulmonary disease in lung cancer or inflammatory bowel disease in colorectal cancer, further exacerbating their vulnerability to this novel pathogen. Given an acute lack of knowledge and concern for extreme vulnerability, the COVID-19 and Cancer Consortium (CCC19) was formed in March 2020 to understand how the novel virus affects cancer patients. While this national effort began organically, primarily through social media, membership has quickly grown to over 450 healthcare professionals and patient advocates representing over 125 institutions and organizations in the US, Canada, and Mexico. Included in this membership are the majority of the NCI-designated Comprehensive Cancer Centers, NCI-Designated Cancer Centers and large networks of community practices, many of which are NCORP sites. The driving goal of the consortium is to collect prospective, granular, uniformly organized information to help generate hypotheses for translational science, and to arm treating providers with the most complete data resource as rapidly as possible on cancer patients infected with COVID-19. As of January 2021, CCC19 has collected over 8000 case reports of high analytical quality, and has published initial results in The Lancet, Cancer Discovery, Cancer Cell, and Nature Cancer. As the Research Coordinating Center for the consortium, we establish and propagate best practices for governance, data collection, and data dissemination. We host the main data registry, conduct data cleaning, quality assurance, and central data analysis, and will work with participant institutions who choose to set up mirrored local databases.

项目摘要 由SARS-CoV-2病毒引起的疾病新冠肺炎目前已影响近1亿人 全球有近200万人死亡。癌症患者在这种情况下具有独特的风险特征 大流行。许多患者，特别是那些积极接受治疗的患者，与 医疗保健系统。这可以包括提供者探访、抽血、成像、社会工作和 为抗癌治疗和支持性护理等提供财务咨询和输液室访问 就像输血一样。尽管在这些共享空间中为减少病毒传播做出了英勇的努力， 患者接触新冠肺炎的风险增加。此外，大多数癌症患者都是 免疫功能减退通过抗癌药物的骨髓毒性作用，支持性 药物，如类固醇，和/或癌症本身；以及60岁以上，将它们放入 新冠肺炎相关发病率和死亡率的最高风险类别。最后，事件的发生 在几种癌症中，重要的合并症可能会显著增加，例如慢性 肺癌中的阻塞性肺疾病或结直肠癌中的炎症性肠病， 进一步加剧了它们对这种新病原体的脆弱性。 鉴于对极端脆弱性的严重缺乏了解和关注，新冠肺炎和 癌症联盟(CCC19)成立于2020年3月，目的是了解这种新型病毒是如何 影响癌症患者。虽然这一国家的努力是有机地开始的，主要是通过社会 媒体，会员迅速增长到450多名医疗保健专业人员和患者 代表美国、加拿大和墨西哥超过125个机构和组织的倡导者。 该成员包括NCI指定的综合癌症的大多数 中心、NCI指定的癌症中心和大型社区实践网络，其中许多 这些都是NCORP站点。该财团的主要目标是收集预期的、细粒度的、 统一组织的信息，以帮助生成翻译科学的假设，并 尽快为癌症患者提供最完整的数据资源 感染了新冠肺炎。截至2021年1月，CCC19已收集了8000多起案件报告 高分析质量，并在《柳叶刀》、《癌症发现》、《癌症》杂志上发表了初步结果 细胞和自然癌症。 作为联合体的研究协调中心，我们建立和宣传最好 治理、数据收集和数据传播的实践。我们托管主数据注册表， 进行数据清理、质量保证和中央数据分析，并将与参与者合作 选择建立镜像本地数据库的机构。